野生型-话题@MedSci - 梅斯（MedSci）

#野生型#

48篇内容 | 1954人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2082906, encodeId=f4772082906bf, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, objectType=article, longId=175430, objectId=98161e54306c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98161e54306c, replyNumber=0, likeNumber=89, createdTime=2020-04-02, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98161e54306c, moduleTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=98161e54306c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082903, encodeId=00b02082903d8, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=J Clin Periodontol: 牙周炎患者牙龈卟啉单胞菌的野生型分离物对血小板活化的影响, objectType=article, longId=142018, objectId=735714201818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=735714201818, replyNumber=0, likeNumber=109, createdTime=2019-04-12, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=735714201818, moduleTitle=J Clin Periodontol: 牙周炎患者牙龈卟啉单胞菌的野生型分离物对血小板活化的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=735714201818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082901, encodeId=46b82082901c5, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, objectType=article, longId=136508, objectId=62cf1365087c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62cf1365087c, replyNumber=0, likeNumber=83, createdTime=2018-09-28, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62cf1365087c, moduleTitle=JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=62cf1365087c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082902, encodeId=efb920829029f, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌, objectType=article, longId=139634, objectId=060d13963424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060d13963424, replyNumber=0, likeNumber=80, createdTime=2019-04-07, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060d13963424, moduleTitle=CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=060d13963424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082900, encodeId=cacd208290036, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Blood：TRRAP对突变型和野生型p53在淋巴瘤中的积累发挥重要的调节作用, objectType=article, longId=135365, objectId=568013536527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568013536527, replyNumber=0, likeNumber=83, createdTime=2018-12-26, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568013536527, moduleTitle=Blood：TRRAP对突变型和野生型p53在淋巴瘤中的积累发挥重要的调节作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=568013536527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082894, encodeId=5a902082894a3, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, objectType=article, longId=108199, objectId=19871081992f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19871081992f, replyNumber=0, likeNumber=77, createdTime=2017-12-13, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19871081992f, moduleTitle=JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=19871081992f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082899, encodeId=1bb7208289995, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌, objectType=article, longId=131020, objectId=199e13102034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199e13102034, replyNumber=0, likeNumber=69, createdTime=2018-11-06, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199e13102034, moduleTitle=EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=199e13102034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082892, encodeId=3bac208289262, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=EUR HEART J：野生型甲状腺素运载蛋白——心脏淀粉样变性的临床特征, objectType=article, longId=103332, objectId=5775103332b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5775103332b9, replyNumber=0, likeNumber=78, createdTime=2017-10-30, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5775103332b9, moduleTitle=EUR HEART J：野生型甲状腺素运载蛋白——心脏淀粉样变性的临床特征, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5775103332b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082893, encodeId=1c902082893a9, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JCO:NSAID可显着改善KRAS野生型患者的生存, objectType=article, longId=104813, objectId=403e10481310, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=403e10481310, replyNumber=0, likeNumber=67, createdTime=2018-04-02, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=403e10481310, moduleTitle=JCO:NSAID可显着改善KRAS野生型患者的生存, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=403e10481310)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082898, encodeId=a6d820828988d, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, objectType=article, longId=123846, objectId=166d123846a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=166d123846a2, replyNumber=0, likeNumber=62, createdTime=2018-01-20, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=166d123846a2, moduleTitle=Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=166d123846a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082895, encodeId=680a2082895b3, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, objectType=article, longId=111675, objectId=74ad1116e521, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ad1116e521, replyNumber=0, likeNumber=142, createdTime=2018-07-21, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ad1116e521, moduleTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=74ad1116e521)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082896, encodeId=9722208289608, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=CLIN CHEM：液体活检靶向重测序如何多重消除野生型DNA？, objectType=article, longId=116615, objectId=74091166154e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74091166154e, replyNumber=0, likeNumber=0, createdTime=2018-01-04, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74091166154e, moduleTitle=CLIN CHEM：液体活检靶向重测序如何多重消除野生型DNA？, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=74091166154e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082897, encodeId=cde4208289ee8, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物, objectType=article, longId=117254, objectId=b6b411e25414, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6b411e25414, replyNumber=0, likeNumber=74, createdTime=2017-10-25, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6b411e25414, moduleTitle=Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b6b411e25414)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082891, encodeId=8a2920828913e, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响, objectType=article, longId=102999, objectId=5d36102999e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d36102999e4, replyNumber=0, likeNumber=81, createdTime=2018-02-14, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d36102999e4, moduleTitle=JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5d36102999e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082890, encodeId=e02e208289035, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗, objectType=article, longId=80610, objectId=9e8d8061024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8d8061024, replyNumber=0, likeNumber=84, createdTime=2017-05-21, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8d8061024, moduleTitle=Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=9e8d8061024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082889, encodeId=f8cd208288920, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), objectType=article, longId=76991, objectId=b8c4e6991d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8c4e6991d8, replyNumber=0, likeNumber=84, createdTime=2016-10-11, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8c4e6991d8, moduleTitle=Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3), moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b8c4e6991d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082888, encodeId=b6792082888c7, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=Circulation：野生型转甲状腺素蛋白淀粉样变性引起的心衰研究, objectType=article, longId=60716, objectId=166d60e162c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=166d60e162c, replyNumber=0, likeNumber=69, createdTime=2016-01-31, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=166d60e162c, moduleTitle=Circulation：野生型转甲状腺素蛋白淀粉样变性引起的心衰研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=166d60e162c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082887, encodeId=9cd1208288efe, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤, objectType=article, longId=59795, objectId=1be659e954c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1be659e954c, replyNumber=0, likeNumber=67, createdTime=2016-01-24, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1be659e954c, moduleTitle=FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1be659e954c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082886, encodeId=58602082886a9, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效, objectType=article, longId=53513, objectId=394753513a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=394753513a0, replyNumber=0, likeNumber=60, createdTime=2015-11-05, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=394753513a0, moduleTitle=JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=394753513a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2082885, encodeId=15a62082885c7, content=<a href='/topic/show?id=2436961068e' target=_blank style='color:#2F92EE;'>#野生型#</a>, objectTitle=招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验, objectType=article, longId=48418, objectId=7c4d4841853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c4d4841853, replyNumber=0, likeNumber=79, createdTime=2015-10-31, rootId=0, userName=ms5106640509429053, userId=d37d2500154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c4d4841853, moduleTitle=招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c4d4841853)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

野生型

2020-05-29

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶

2020-04-02

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

J Clin Periodontol: 牙周炎患者牙龈卟啉单胞菌的野生型分离物对血小板活化的影响

2019-04-12

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA ONCOL：西妥昔单抗+改良FOLFOXIR后持续西妥昔单抗或贝伐单抗治疗RAS和BRAF野生型转移性结直肠癌I

2018-09-28

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

CLIN CANCER RES：Duligotuzumab联合FOLFIRI方案治疗RAS野生型转移性结直肠癌

2019-04-07

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Blood：TRRAP对突变型和野生型p53在淋巴瘤中的积累发挥重要的调节作用

2018-12-26

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA：KRAS野生型晚期或转移性结直肠癌：西妥昔单抗 vs 贝伐珠单抗

2017-12-13

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

EUR J Cancer：帕尼单抗联合顺铂/吉西他滨治疗KRAS野生型胆管癌

2018-11-06

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

EUR HEART J：野生型甲状腺素运载蛋白——心脏淀粉样变性的临床特征

2017-10-30

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JCO:NSAID可显着改善KRAS野生型患者的生存

2018-04-02

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Lancet Gastroen Hepatol：BRAF， PIK3CA， KRAS以及 NRAS野生型晚期或转移性结直肠癌患者多信号通路联合治疗研究

2018-01-20

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗

2018-07-21

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

CLIN CHEM：液体活检靶向重测序如何多重消除野生型DNA？

2018-01-04

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Brit J Cancer：RAS野生型转移性结肠癌患者接受抗EGFR治疗响应的蛋白预测生物标志物

2017-10-25

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA:一线化疗联合Cetuximab 或 Bevacizumab对KRAS野生型晚期或转移性结肠直肠癌患者生存的影响

2018-02-14

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Br J Cancer：野生型KRAS或RAS转移性结直肠癌：帕尼单抗联合更佳支持治疗

2017-05-21

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Lancet Oncol：RAS野生型结直肠癌：FOLFIRI+西妥昔 vs FOLFIRI+贝伐珠(FIRE-3)

2016-10-11

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

Circulation：野生型转甲状腺素蛋白淀粉样变性引起的心衰研究

2016-01-31

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

FDA：PD-1免疫疗法Opdivo（nivolumab）再获批准——单药一线治疗BRAF野生型黑色素瘤

2016-01-24

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

JAMA Oncol：nivolumab对于治疗野生型或突变的BRAF晚期黑色素瘤患者安全且有疗效

2015-11-05

ms5106640509429053 (审核中...)

前往app查看评论内容

#野生型#

招募患者：阿帕替尼治疗晚期EGFR野生型肺癌Ⅲ期临床试验

2015-10-31

科室
- - 订阅+
  - 更多科室
工具
服务